Neuroprotective effects of ethyl-eicosapentaenoic acid in first episode psychosis: A longitudinal T2 relaxometry pilot study

Stephen J. Wood; Luca Cocchi; Tina Marie Proffitt; Mirabel McConchie; Graeme D. Jackson; Tsutomu Takahashi; Christos Pantelis; Patrick D. McGorry; Gregor E. Berger

doi:10.1016/j.pscychresns.2009.12.003

Neuroprotective effects of ethyl-eicosapentaenoic acid in first episode psychosis: A longitudinal T₂ relaxometry pilot study

Stephen J. Wood^*, Luca Cocchi, Tina Marie Proffitt, Mirabel McConchie, Graeme D. Jackson, Tsutomu Takahashi, Christos Pantelis, Patrick D. McGorry, Gregor E. Berger

^*Corresponding author for this work

Neuropsychiatry

Research output: Contribution to journal › Article › peer-review

29 Scopus citations

Abstract

We used magnetic resonance imaging to examine the effect of ethyl-eicosapentaenoic acid (E-EPA) on hippocampal T₂ relaxation time in first episode psychosis patients at baseline and after 12weeks of follow-up. There was an increase in T₂ in the placebo group but not in the E-EPA group, suggesting a neuroprotective effect of E-EPA treatment. In addition, the smaller the increase in T₂, the greater the improvement in negative symptoms.

Original language	English
Pages (from-to)	180-182
Number of pages	3
Journal	Psychiatry Research - Neuroimaging
Volume	182
Issue number	2
DOIs	https://doi.org/10.1016/j.pscychresns.2009.12.003
State	Published - 2010/05

Keywords

Hippocampus
MRI
Neuroprotection
Schizophrenia

ASJC Scopus subject areas

Neuroscience (miscellaneous)
Radiology Nuclear Medicine and imaging
Psychiatry and Mental health

Access to Document

10.1016/j.pscychresns.2009.12.003

Cite this

Wood, S. J., Cocchi, L., Proffitt, T. M., McConchie, M., Jackson, G. D., Takahashi, T., Pantelis, C., McGorry, P. D., & Berger, G. E. (2010). Neuroprotective effects of ethyl-eicosapentaenoic acid in first episode psychosis: A longitudinal T₂ relaxometry pilot study. Psychiatry Research - Neuroimaging, 182(2), 180-182. https://doi.org/10.1016/j.pscychresns.2009.12.003

@article{4a537767347740b3a417c05ae7ed5237,

title = "Neuroprotective effects of ethyl-eicosapentaenoic acid in first episode psychosis: A longitudinal T2 relaxometry pilot study",

abstract = "We used magnetic resonance imaging to examine the effect of ethyl-eicosapentaenoic acid (E-EPA) on hippocampal T2 relaxation time in first episode psychosis patients at baseline and after 12weeks of follow-up. There was an increase in T2 in the placebo group but not in the E-EPA group, suggesting a neuroprotective effect of E-EPA treatment. In addition, the smaller the increase in T2, the greater the improvement in negative symptoms.",

keywords = "Hippocampus, MRI, Neuroprotection, Schizophrenia",

author = "Wood, {Stephen J.} and Luca Cocchi and Proffitt, {Tina Marie} and Mirabel McConchie and Jackson, {Graeme D.} and Tsutomu Takahashi and Christos Pantelis and McGorry, {Patrick D.} and Berger, {Gregor E.}",

note = "Funding Information: This work was supported by two NH&MRC project grants (ID: 145627 ; 209062 ), a NH&MRC program grant (ID: 350241 ), and the Colonial Foundation, Melbourne, Australia . A/Prof Wood is supported by a Clinical Career Development Award from the NH&MRC, and Dr Cocchi by a Swiss National Science Foundation young investigator award ( PBLAB3-119622 ). A Margaret & Walter Lichtenstein Foundation award (University of Basel) supported Dr Berger. These funding sources had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. None of the authors has a conflict of interest with any manufacturer or distributor of omega-3 fatty acids. The presented data were part of an investigator-initiated trial. Laxdale Ltd (now owned by Amarin Corporation) provided the study medication for free. None of the research centres received any financial support from Laxdale Ltd.",

year = "2010",

month = may,

doi = "10.1016/j.pscychresns.2009.12.003",

language = "英語",

volume = "182",

pages = "180--182",

journal = "Psychiatry Research - Neuroimaging",

issn = "0925-4927",

publisher = "Elsevier Ireland Ltd",

number = "2",

}

TY - JOUR

T1 - Neuroprotective effects of ethyl-eicosapentaenoic acid in first episode psychosis

T2 - A longitudinal T2 relaxometry pilot study

AU - Wood, Stephen J.

AU - Cocchi, Luca

AU - Proffitt, Tina Marie

AU - McConchie, Mirabel

AU - Jackson, Graeme D.

AU - Takahashi, Tsutomu

AU - Pantelis, Christos

AU - McGorry, Patrick D.

AU - Berger, Gregor E.

N1 - Funding Information: This work was supported by two NH&MRC project grants (ID: 145627 ; 209062 ), a NH&MRC program grant (ID: 350241 ), and the Colonial Foundation, Melbourne, Australia . A/Prof Wood is supported by a Clinical Career Development Award from the NH&MRC, and Dr Cocchi by a Swiss National Science Foundation young investigator award ( PBLAB3-119622 ). A Margaret & Walter Lichtenstein Foundation award (University of Basel) supported Dr Berger. These funding sources had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. None of the authors has a conflict of interest with any manufacturer or distributor of omega-3 fatty acids. The presented data were part of an investigator-initiated trial. Laxdale Ltd (now owned by Amarin Corporation) provided the study medication for free. None of the research centres received any financial support from Laxdale Ltd.

PY - 2010/5

Y1 - 2010/5

N2 - We used magnetic resonance imaging to examine the effect of ethyl-eicosapentaenoic acid (E-EPA) on hippocampal T2 relaxation time in first episode psychosis patients at baseline and after 12weeks of follow-up. There was an increase in T2 in the placebo group but not in the E-EPA group, suggesting a neuroprotective effect of E-EPA treatment. In addition, the smaller the increase in T2, the greater the improvement in negative symptoms.

AB - We used magnetic resonance imaging to examine the effect of ethyl-eicosapentaenoic acid (E-EPA) on hippocampal T2 relaxation time in first episode psychosis patients at baseline and after 12weeks of follow-up. There was an increase in T2 in the placebo group but not in the E-EPA group, suggesting a neuroprotective effect of E-EPA treatment. In addition, the smaller the increase in T2, the greater the improvement in negative symptoms.

KW - Hippocampus

KW - MRI

KW - Neuroprotection

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=77952673349&partnerID=8YFLogxK

U2 - 10.1016/j.pscychresns.2009.12.003

DO - 10.1016/j.pscychresns.2009.12.003

M3 - 学術論文

C2 - 20413278

AN - SCOPUS:77952673349

SN - 0925-4927

VL - 182

SP - 180

EP - 182

JO - Psychiatry Research - Neuroimaging

JF - Psychiatry Research - Neuroimaging

IS - 2

ER -